Secretory leukocyte protease inhibitor concentration increases in amnioticfluid with the onset of labour in women: characterization of sites of release within the uterus
Fc. Denison et al., Secretory leukocyte protease inhibitor concentration increases in amnioticfluid with the onset of labour in women: characterization of sites of release within the uterus, J ENDOCR, 161(2), 1999, pp. 299-306
Secretory leukocyte protease inhibitor is a potent inhibitor of neutrophil
function, a mediator of mucosal immunity and an inhibitor of NF kappa B reg
ulated inflammatory responses. However, its source, function and regulation
within the uterus during pregnancy and at parturition are not well defined
. In amniotic fluid, the concentration of secretory leukocyte protease inhi
bitor increased significantly from 2nd trimester (24 +/- 3 ng/ml; mean +/-
S.E.M.; n=20) to term (751 +/- 53 ng/ml; P<0.05; n=15) with a further profo
und increase (P<0.005) with the onset of labour (3929 +/- 1076 ng/ml; n=15)
. To establish the intrauterine sites of secretion, explants (n=6 different
patients per tissue) were collected at term after elective caesarean secti
on. High levels of secretory leukocyte protease inhibitor were released by
decidua (135.2 +/- 12.4 pg/mg; mean +/- S.E.M.) and chono-decidua (325.1 +/
- 26.4 pg/mg) with less by amnion (55.6 +/- 6.0 pg/mg) and placenta (9.2 +/
- 1.9 pg/mg). Intense immunoreactivity for secretory leukocyte protease inh
ibitor was detected predominantly in decidua parietalis cells adherent to t
he chorion laeve and myometrium, and also in decidua basalis. We propose th
at, within the pregnant uterus, secretory leukocyte protease inhibitor is r
eleased by decidua, fetal membranes and potentially the fetal lung. The inc
rease in secretory leukocyte protease inhibitor may act to modulate proinfl
ammatory paracrine interactions for the maintenance of pregnancy and limit
those occurring at parturition within the uterus.